CN116113641A - 新型内－β－N－乙酰氨基葡萄糖苷酶 - Google Patents

新型内－β－N－乙酰氨基葡萄糖苷酶 Download PDF

Info

Publication number
CN116113641A
CN116113641A CN202180054259.2A CN202180054259A CN116113641A CN 116113641 A CN116113641 A CN 116113641A CN 202180054259 A CN202180054259 A CN 202180054259A CN 116113641 A CN116113641 A CN 116113641A
Authority
CN
China
Prior art keywords
leu
lys
asp
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180054259.2A
Other languages
English (en)
Chinese (zh)
Inventor
西泽华子
小野泰典
岩本充广
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN116113641A publication Critical patent/CN116113641A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202180054259.2A 2020-09-02 2021-09-01 新型内－β－N－乙酰氨基葡萄糖苷酶 Pending CN116113641A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-147745 2020-09-02
JP2020147745 2020-09-02
PCT/JP2021/032083 WO2022050300A1 (ja) 2020-09-02 2021-09-01 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ

Publications (1)

Publication Number Publication Date
CN116113641A true CN116113641A (zh) 2023-05-12

Family

ID=80492267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180054259.2A Pending CN116113641A (zh) 2020-09-02 2021-09-01 新型内－β－N－乙酰氨基葡萄糖苷酶

Country Status (9)

Country Link
US (1) US20240336907A1 (https=)
EP (1) EP4209506A4 (https=)
JP (1) JP7798773B2 (https=)
KR (1) KR20230061360A (https=)
CN (1) CN116113641A (https=)
AU (1) AU2021338014A1 (https=)
CA (1) CA3191395A1 (https=)
TW (1) TW202227479A (https=)
WO (1) WO2022050300A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118308329A (zh) * 2024-06-11 2024-07-09 中国海洋大学 β-N-乙酰氨基己糖苷酶D297K及其应用
CN118325869A (zh) * 2024-06-12 2024-07-12 上海盛迪医药有限公司 一种内-β-N-乙酰葡糖苷酶变体
WO2025148976A1 (zh) * 2024-01-10 2025-07-17 上海齐鲁制药研究中心有限公司 新型beta-N-乙酰氨基葡萄糖苷内切酶及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
TW202342106A (zh) 2022-02-09 2023-11-01 日商第一三共股份有限公司 環境應答性遮蔽抗體及其利用
CN118804983A (zh) 2022-03-02 2024-10-18 第一三共株式会社 含Fc分子的制造方法
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
KR20250064682A (ko) 2022-09-09 2025-05-09 다이이찌 산쿄 가부시키가이샤 신규 올리고당, 그 올리고당의 제조 중간체, 및 그것들의 제조 방법
JP2024054523A (ja) * 2022-10-05 2024-04-17 日本マイクロバイオファーマ株式会社 抗体薬物複合体の製造方法及びそれに用いる酵素
KR20250138255A (ko) 2023-01-27 2025-09-19 다이이찌 산쿄 가부시키가이샤 항 lrrc15 항체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180057804A1 (en) * 2016-08-24 2018-03-01 CHO Pharma Inc. Endoglycosidase mutants for glycoprotein remodeling and methods of using it
CN108026518A (zh) * 2015-07-16 2018-05-11 第三共株式会社 新型endos突变型酶
WO2019065964A1 (ja) * 2017-09-29 2019-04-04 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
WO2020006176A1 (en) * 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795349C (en) 2010-04-15 2016-11-29 Seattle Genetics, Inc. Targeted pyrrolobenzodiazepine conjugates
IN2014DN06806A (https=) 2012-02-10 2015-05-22 Univ Maryland
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
KR20160047567A (ko) 2013-08-28 2016-05-02 스템센트알엑스 인코포레이티드 조작된 항-dll3 접합체 및 사용 방법
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
KR102337414B1 (ko) 2013-12-16 2021-12-10 제넨테크, 인크. 펩타이드 모방체 화합물 및 이의 항체-약물 컨쥬게이트
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
DE102014214408A1 (de) 2014-07-23 2016-01-28 Wacker Chemie Ag Härtbare Organopolysiloxanzusammensetzungen
BR102014018190B1 (pt) 2014-07-24 2020-10-20 Fabio Eduardo Sabonge Cunha suporte para placa de sinalização vertical
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
EP4530348A3 (en) 2014-12-15 2025-08-06 Basf Se Detergent composition comprising subtilase variants
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
SMT202000614T1 (it) 2015-06-29 2021-01-05 Immunogen Inc Coniugati di anticorpi ingegnerizzati con cisteina
JP6744738B2 (ja) * 2015-06-29 2020-08-19 公益財団法人野口研究所 グライコシンターゼ
SG10202005460RA (en) 2015-06-30 2020-07-29 Seattle Genetics Inc Anti-ntb-a antibodies and related compositions and methods
GB201513607D0 (en) 2015-07-31 2015-09-16 Feingold Jay M Pyrrolobenzodiazepine-antibody conjugates
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
KR102789862B1 (ko) 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
WO2017124084A1 (en) 2016-01-15 2017-07-20 University Of Maryland, College Park Endo-s2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
WO2018003983A1 (ja) 2016-07-01 2018-01-04 第一三共株式会社 ｈＡＮＰ－Ｆｃ含有分子コンジュゲート
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
PT3523287T (pt) 2016-10-04 2021-10-06 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting
US11001605B2 (en) 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
US11242593B2 (en) 2016-11-30 2022-02-08 Jfe Steel Corporation Steel for nitrocarburizing, and component
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
JP7510249B2 (ja) 2018-07-28 2024-07-03 公益財団法人野口研究所 複合型糖鎖を遊離する方法
EP3848054B1 (en) * 2018-09-06 2025-01-29 Daiichi Sankyo Company, Limited Antibody-drug conjugates of cyclic dinucleotide derivatives
JP6732150B1 (ja) 2019-03-06 2020-07-29 東京インキ株式会社 熱ラミネート用スチレンフィルム用グラビア印刷インキ組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026518A (zh) * 2015-07-16 2018-05-11 第三共株式会社 新型endos突变型酶
US20180208915A1 (en) * 2015-07-16 2018-07-26 Daiichi Sankyo Company, Limited Novel endos mutant enzyme
US20180057804A1 (en) * 2016-08-24 2018-03-01 CHO Pharma Inc. Endoglycosidase mutants for glycoprotein remodeling and methods of using it
WO2019065964A1 (ja) * 2017-09-29 2019-04-04 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
WO2020006176A1 (en) * 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
IWAMOTO M等: "Generation of efficient mutants of endoglycosidase fromStreptococcus pyogenes and their application in a novel one-pot trransglycosylation reaction for antibody modification", PLOS ONE, vol. 13, no. 2, 23 February 2018 (2018-02-23), pages 4 *
LI T等: "Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 32, 5 August 2016 (2016-08-05) *
NCBI: "endo-beta-N-acetylglucosaminidase [Streptococcus iniae]", GENBANK, 23 November 2018 (2018-11-23) *
SHIVATARE SS等: "Development of glycosynthases with broad glycan specificity for the efficient glyco-remodeling of anntibodies", CHEMICAL COMMUNICATIOS, vol. 54, no. 48, 29 May 2018 (2018-05-29), pages 4 - 5 *
凌沛学: "《生物医药及高性能医疗器械 中国制造2025大众读本》", 30 April 2018, 山东科学技术出版社, pages: 102 *
厉朝龙: "《生物化学与分子生物学》", 31 August 2001, 中国医药科技出版社, pages: 585 *
吴梧桐: "《生物制药工艺学》", 29 February 2004, 中国医药科技出版社, pages: 546 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025148976A1 (zh) * 2024-01-10 2025-07-17 上海齐鲁制药研究中心有限公司 新型beta-N-乙酰氨基葡萄糖苷内切酶及其用途
CN118308329A (zh) * 2024-06-11 2024-07-09 中国海洋大学 β-N-乙酰氨基己糖苷酶D297K及其应用
CN118308329B (zh) * 2024-06-11 2024-08-06 中国海洋大学 β-N-乙酰氨基己糖苷酶D297K及其应用
CN118325869A (zh) * 2024-06-12 2024-07-12 上海盛迪医药有限公司 一种内-β-N-乙酰葡糖苷酶变体

Also Published As

Publication number Publication date
CA3191395A1 (en) 2022-03-10
AU2021338014A1 (en) 2023-03-09
EP4209506A1 (en) 2023-07-12
JPWO2022050300A1 (https=) 2022-03-10
JP7798773B2 (ja) 2026-01-14
KR20230061360A (ko) 2023-05-08
US20240336907A1 (en) 2024-10-10
WO2022050300A1 (ja) 2022-03-10
TW202227479A (zh) 2022-07-16
EP4209506A4 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
CN116113641A (zh) 新型内－β－N－乙酰氨基葡萄糖苷酶
CN108026518B (zh) 新型endos突变型酶
US11713453B2 (en) Enzymes for trimming of glycoproteins
Giddens et al. Endo-F3 glycosynthase mutants enable chemoenzymatic synthesis of core-fucosylated triantennary complex type glycopeptides and glycoproteins
Wei et al. Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation
JP2022023160A (ja) グリコシンターゼとしてのＥｎｄｏ－Ｓ２変異体、糖タンパク質の製造方法および糖タンパク質の糖鎖操作のための使用
KR102282930B1 (ko) Crm197 및 관련 단백질의 발현 및 정제
WO2019234021A1 (en) Glycoengineered monoclonal antibody
WO2023167238A1 (ja) Ｆｃ含有分子の製造方法
Fan et al. Enhanced antibody-defucosylation capability of α-L-fucosidase by proximity-based protein fusion
KR101755430B1 (ko) 개선된 효율을 갖는 시알산전달효소를 이용한 당단백질의 당사슬에 시알산을 부가하는 방법
NL2022013B1 (en) Polypeptide Conjugates
WO2025067404A1 (zh) 糖苷内切酶s2突变体、其制备方法及其在抗体糖基化改造中的应用
HK40096983A (en) Novel endo-?-n-acetylglucosaminidase
WO2015102501A1 (en) Method for industrial scale production of therapeutically active proteins of desired glycosylation pattern
WO2025250633A1 (en) Glycosynthase mutants for antibody-drug conjugate engineering
HK1248271B (en) Endos mutant enzyme

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination